Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease - Wikidata - awgldk - TriplyDB

Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease

Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease

http://www.wikidata.org/entity/Q34473323

about

Neuroinflammation in Parkinson's disease and its potential as therapeutic target A Neurologist's Guide to TNF Biology and to the Principles behind the Therapeutic Removal of Excess TNF in Disease Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?M1 and M2 immune activation in Parkinson's Disease: Foe and ally?Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents Toxin-Induced Experimental Models of Learning and Memory Impairment Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease.Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery.Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease?Evidence of inflammatory system involvement in Parkinson's disease.Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma.Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease.Psychological stress in adolescent and adult mice increases neuroinflammation and attenuates the response to LPS challenge.Regulator of G-protein signaling-10 negatively regulates NF-κB in microglia and neuroprotects dopaminergic neurons in hemiparkinsonian rats.Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.RGS10 exerts a neuroprotective role through the PKA/c-AMP response-element (CREB) pathway in dopaminergic neuron-like cells.LRRK2 inhibition attenuates microglial inflammatory responses Down-regulation of p21-activated serine/threonine kinase 1 is involved in loss of mesencephalic dopamine neurons.Progranulin does not bind tumor necrosis factor (TNF) receptors and is not a direct regulator of TNF-dependent signaling or bioactivity in immune or neuronal cells.Gene-based therapies in Parkinson's disease.β-arrestin protects neurons by mediating endogenous opioid arrest of inflammatory microglia.Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?The role of innate and adaptive immunity in Parkinson's disease.Advances in non-dopaminergic treatments for Parkinson's disease Sulfhydryl-mediated redox signaling in inflammation: role in neurodegenerative diseases.Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.Diterpenes: Advances in Neurobiological Drug Research.Microglial phenotypes in Parkinson's disease and animal models of the disease.Translocator protein 18 kDa negatively regulates inflammation in microglia.Microglial TNF-α mediates enhancement of dopaminergic degeneration by brain angiotensin.Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease.Regulation of microglia effector functions by tumor necrosis factor signaling.MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration.Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats.Human pluripotent stem cell derived midbrain PITX3(eGFP/w) neurons: a versatile tool for pharmacological screening and neurodegenerative modeling.Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease.

P2860

Q26783305-89B6AECF-3273-47D0-90C2-A03FDD6B85D0 Q26801912-7BAC9EA5-12CF-4420-9AEA-34A9E4E19FDC Q27015811-2599BFC5-403A-4D17-A108-D5129FC53135 Q27024667-382E19F4-382F-41A3-97CC-9E100FC91198 Q27027973-86C10692-CDD1-4E70-B86B-256C925DB138 Q27334472-F0A5108A-78A2-4A2A-9FC2-8A4619BADBC8 Q28075692-24BA3218-BDC7-413F-BA98-AF33DF24B100 Q28075913-A02ACE9A-A4C2-4CE1-A2E9-1C0AA93854D6 Q30512976-3E7D2CB2-1AFF-4562-AE91-E421BEE2748F Q30624869-4010B9D3-BF74-48FE-8EBA-6694A21D642B Q33353554-038D1090-4544-4E31-8B02-6C9BEE4DE8F8 Q33890818-5CEA0CEA-7949-4B96-8C34-2483A2F547E6 Q34339649-A8797159-3721-4910-B258-31DD1891D99F Q35510197-85C841CA-F0D0-4AE8-85CB-DD17A84B78AB Q35768866-B0524300-0746-4908-8BAC-E3C28F672F47 Q35889059-FBC46DD2-31D5-4AA8-9724-E4366B7F5A91 Q35925767-4A947D3E-1242-4DA4-8607-F6109F8C13CC Q36213563-129251EA-854F-4FE8-9FB1-4A6AF3D745B7 Q36493605-08439CF4-EFC1-4B74-9C91-EDC90C6933E9 Q36846653-69394FCC-7295-4706-8647-CDDF350D918A Q36999042-5DF4C72A-8543-4478-8A1B-310BCBF0A456 Q37506503-8D1E9F04-FA1B-4E8E-BFF8-6BFD429F0CE5 Q37578793-9F478829-BF64-4084-81E9-65C9990E99B4 Q38103856-19E42903-6306-4C89-978C-0AF6264C3EB2 Q38166155-10B8888F-80A1-4A73-8A73-F9FDDEECC156 Q38218083-CFD285F5-F863-4FB0-B639-5F340DF5CC69 Q38397575-1381FAE6-865A-43B1-AAB4-7E811AC9D069 Q38541943-F0C88DDE-E302-445C-A373-1F23635F8BCB Q38556918-0487C963-309F-4577-9DDC-F6BBA742ACFA Q38791506-D7614435-2932-4EBA-B427-959DD64F6258 Q38815779-91E05122-942D-4824-A545-EEDE134904E4 Q39009678-6D2B3B5E-8CC0-427B-A6A0-8AAEB79EE802 Q39055955-BFA68455-AF04-4904-8457-62B64FEBE0CA Q39392775-D9582E8E-8C00-4FB7-9250-29802CCD5FB2 Q39459840-75E749F9-DD44-4FAB-9900-3F051EAFB27C Q41894807-5E932F06-C60A-411B-90F0-7D01CFB23B1F Q42001519-4F2B78D0-DEB8-4373-B472-68E180795846 Q42030555-27E46BA0-460F-4EDD-8E58-7477191E6AB9 Q55240777-E4F4BEE2-7375-483C-95BC-CF14D547CECB

P2860

Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease

http://www.wikidata.org/entity/Q34473323

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Delayed dominant-negative TNF ...... t model of Parkinson's disease

@ast

Delayed dominant-negative TNF ...... t model of Parkinson's disease

@en

Delayed dominant-negative TNF ...... t model of Parkinson's disease

@nl

type

label

Delayed dominant-negative TNF ...... t model of Parkinson's disease

@ast

Delayed dominant-negative TNF ...... t model of Parkinson's disease

@en

Delayed dominant-negative TNF ...... t model of Parkinson's disease

@nl

prefLabel

Delayed dominant-negative TNF ...... t model of Parkinson's disease

@ast

Delayed dominant-negative TNF ...... t model of Parkinson's disease

@en

Delayed dominant-negative TNF ...... t model of Parkinson's disease

@nl

P1433

Q34473323-D21758B4-BD76-46DA-9828-00238C46CB0F

P1476

Q34473323-5E29A7EA-6CF8-4FF9-BB0E-C206C0167826

P2093

Q34473323-5A6EE37D-83F4-4458-A9EC-FD928DD8F76B

Q34473323-87CCDA96-131A-46F1-B294-FCF28BAA7141

Q34473323-A8F32D07-3BA2-4DD2-99E5-110DC5B1B227

P2860

Q34473323-08F8015A-032E-47E3-B07F-166501330478

Q34473323-1CC580B2-DD20-4E5B-8904-4AF6B3D21A3C

Q34473323-1D7C6650-4447-445B-BDBC-A635FF8D2128

Q34473323-2D0611FC-9855-4504-A3B1-4DA5DF90CFA3

Q34473323-409EAFC5-B2DB-4C78-8935-3A4E635001EA

Q34473323-446AA0A3-DF11-44DC-A9B4-4BDDA0D36783

Q34473323-545F762A-5EB2-4C1E-AFAE-314F5683C01B

Q34473323-5E5BD4E5-5474-4753-997F-D638F30D4811

Q34473323-687C63B8-FFCB-48DF-99C9-9CE67B676286

Q34473323-719CD792-28DA-4A0B-B67C-6A53C5EBECFB

P304

Q34473323-A892B7AE-1C1A-4B07-AC88-129372AA50D9

P31

Q34473323-6F3F2BF4-0F4D-4C65-AC73-0003773F2DBE

P356

Q34473323-70BAE54A-8994-457F-859E-89896FD268F5

P433

Q34473323-F4F37748-23C6-40DD-9D26-5ED125D15D4D

P478

Q34473323-2EC580A4-F082-412B-B22B-5345CADE030E

P50

Q34473323-1F806F07-04C2-436E-B371-580614214FDD

Q34473323-24A8F1E6-8BB9-4FA3-9A27-E1C0812E4661

Q34473323-8F8EBC9D-F1FB-4233-A0D9-3CB04E9B81E8

Q34473323-9A820105-0199-4713-9906-D888BF72F6B5

P577

Q34473323-ACDB31A3-4259-46D5-A912-7C5ABAB88BE7

P5875

Q34473323-FDDA083B-CC50-4D69-B820-05B6F84A70AD

P698

Q34473323-3DF9CA1C-6A44-4BAA-B3A6-7EF7C0021923

P921

Q34473323-58358708-094C-4169-B355-CF8B85697E7B

Q34473323-9C046AAE-394C-4490-9697-0159756473F4

Q34473323-BC03153C-494F-4F22-9EC7-CEA7360B89D3

Q34473323-FEC23833-3AAA-49B6-A7E2-302978A412DE

P932

Q34473323-24D6C32F-3CAA-42D0-AB3A-5F6BFCB2633C

P356

P1433

Molecular Therapy

P1476

Delayed dominant-negative TNF ...... t model of Parkinson's disease

@en

P2093

Christopher J Barnum

http://www.w3.org/2001/XMLSchema#string

Kelly A Ruhn

http://www.w3.org/2001/XMLSchema#string

Steve Varghese

http://www.w3.org/2001/XMLSchema#string

P2860

TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease

Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease

Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha1

Inactivation of TNF signaling by rationally designed dominant-negative TNF variants

Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease

Does neuroinflammation fan the flame in neurodegenerative diseases?

Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator

Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos.

Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS

Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation.

P304

46-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2010.217

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Malú Gámez Tansey

P577

2010-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47500372

http://www.w3.org/2001/XMLSchema#string

P698

20959812

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3017447

http://www.w3.org/2001/XMLSchema#string